Literature DB >> 22076322

Rosacea as a disease of cathelicidins and skin innate immunity.

Kenshi Yamasaki1, Richard L Gallo.   

Abstract

Rosacea is a common and chronic inflammatory skin disease most frequently seen in groups of genetically related individuals. Although the symptoms of rosacea are heterogeneous, they are all related by the presence of characteristic facial or ocular inflammation involving both the vascular and tissue stroma. Until recently, the pathophysiology of this disease was limited to descriptions of a wide variety of factors that exacerbate or improve disease. Recent molecular studies show a common link between the triggers of rosacea and the cellular response, and these observations suggest that an altered innate immune response is involved in disease pathogenesis. Understanding rosacea as a disorder of innate immunity explains the benefits of current treatments and suggests new therapeutic strategies for alleviating this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076322     DOI: 10.1038/jidsymp.2011.4

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  38 in total

Review 1.  Clinical, cellular, and molecular aspects in the pathophysiology of rosacea.

Authors:  Martin Steinhoff; Jörg Buddenkotte; Jerome Aubert; Mathias Sulk; Pawel Novak; Verena D Schwab; Christian Mess; Ferda Cevikbas; Michel Rivier; Isabelle Carlavan; Sophie Déret; Carine Rosignoli; Dieter Metze; Thomas A Luger; Johannes J Voegel
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

2.  Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.

Authors:  Timo Buhl; Mathias Sulk; Pawel Nowak; Jörg Buddenkotte; Ian McDonald; Jérôme Aubert; Isabelle Carlavan; Sophie Déret; Pascale Reiniche; Michel Rivier; Johannes J Voegel; Martin Steinhoff
Journal:  J Invest Dermatol       Date:  2015-04-07       Impact factor: 8.551

Review 3.  Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit.

Authors:  Aimee M Two; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

Review 4.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

5.  [The skin's own antibiotics. Important features of antimicrobial peptides for clinical practice].

Authors:  J Cordes; M Wittersheim; J Harder; R Gläser
Journal:  Hautarzt       Date:  2014-01       Impact factor: 0.751

6.  Single Nucleotide Polymorphisms in the BDNF, VDR, and DNASE 1 Genes in Dry Eye Disease Patients: A Case-Control Study.

Authors:  Joelle A Hallak; Sapna Tibrewal; Neil Mohindra; Xiaoyi Gao; Sandeep Jain
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

7.  Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

8.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

Review 9.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

10.  Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.

Authors:  Alvin B Coda; Tissa Hata; Jeremiah Miller; David Audish; Paul Kotol; Aimee Two; Faiza Shafiq; Kenshi Yamasaki; Julie C Harper; James Q Del Rosso; Richard L Gallo
Journal:  J Am Acad Dermatol       Date:  2013-07-18       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.